Excellent Repigmentation of Generalized Vitiligo with Oral Baricitinib Combined with NB-UVB Phototherapy

Vitiligo is an acquired autoimmune skin disorder, clinically characterized by distinct white macules and patches resulting from progressive melanocyte destruction. JAK-STAT pathway plays an important role in the loss of epidermal melanocytes. Baricitinib can block the JAK-STAT pathway and the downstream chemokines as a new JAK1/2 inhibitor. In this report, we describe the successful treatment of 2 patients with oral baricitinib combined with NB-UVB phototherapy, which provides a good alternative and supplementary to treat refractory vitiligo.

 

Comments：

It is true that vitiligo is an autoimmune skin disorder characterized by the loss of melanocytes in the skin, and that the JAK-STAT pathway plays an important role in this process.

Baricitinib is a JAK1/2 inhibitor that has been approved for the treatment of rheumatoid arthritis and is currently being studied for its potential in treating various other autoimmune disorders, including vitiligo. By inhibiting the JAK-STAT pathway, baricitinib can help prevent the destruction of melanocytes and reduce inflammation in the skin.

NB-UVB phototherapy is a well-established treatment for vitiligo that involves exposing the skin to narrowband ultraviolet B light. This treatment can help stimulate the production of melanocytes and improve repigmentation of the affected areas.

Combining oral baricitinib with NB-UVB phototherapy may provide a complementary approach to treating vitiligo, particularly in patients who have not responded well to other treatments. However, it is important to note that further research is needed to fully evaluate the safety and efficacy of this treatment approach, and to identify which patients may benefit the most from this treatment.

Related Products

Cat.No.	Product Name	Information
S2851	Baricitinib	Baricitinib is a selective JAK1 and JAK2 inhibitor with IC50 of 5.9 nM and 5.7 nM in cell-free assays, ~70 and ~10-fold selective versus JAK3 and Tyk2, no inhibition to c-Met and Chk2. Baricitinib is found to reduce or interrupt the passage of the virus into target cells and is used in the treatment research for COVID-19. Phase 3.

Related Targets

COVID-19 JAK